The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in ...

<li /> 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with ...

BASEL, Switzerland I June 04, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for ...

André Hoffmann, the vice chairman and major shareholder of pharmaceutical giant Roche, sees protecting nature as the only ...

The European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature ...

Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.S.-made drugs ...

GENEVA — Swiss pharmaceuticals powerhouse Roche announced Monday it plans to invest $50 billion in the United States over the next five years, creating 12,000 jobs. The Basel-based company ...

Swiss pharmaceuticals powerhouse Roche announced that it would invest $50bn (around €47bn) in the United States over the next five years, creating 12,000 jobs. The announcement comes as US ...

SINGAPORE] Enigma Health, a healthcare artificial intelligence (AI) spin-off from SingHealth Duke-NUS Academic Medical Centre ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...